MA30815B1 - Medicament combine - Google Patents

Medicament combine

Info

Publication number
MA30815B1
MA30815B1 MA31822A MA31822A MA30815B1 MA 30815 B1 MA30815 B1 MA 30815B1 MA 31822 A MA31822 A MA 31822A MA 31822 A MA31822 A MA 31822A MA 30815 B1 MA30815 B1 MA 30815B1
Authority
MA
Morocco
Prior art keywords
combined medicine
combination
agent
invention involves
her2 inhibitor
Prior art date
Application number
MA31822A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Toshiya Tamura
Shinji Takagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30815B1 publication Critical patent/MA30815B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN AGENT PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE HER2 ET UN AGENT THÉRAPEUTIQUE HORMONAL OU UN AGENT ANTICANCÉREUX EN COMBINAISON. LA PRÉSENTE INVENTION CONCERNE UN AGENT PHARMACEUTIQUE CONTENANT (1) UN INHIBITEUR DE HER2 PRÉSENTANT UN SQUELETTE PYRROLOPYRIMIDINE OU UN SQUELETTE PYRAZOLOPYRIMIDINE, ET (2) UN AGENT THÉRAPEUTIQUE HORMONAL OU UN AGENT ANTICANCÉREUX EN COMBINAISON.
MA31822A 2006-10-06 2009-04-27 Medicament combine MA30815B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07

Publications (1)

Publication Number Publication Date
MA30815B1 true MA30815B1 (fr) 2009-10-01

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31822A MA30815B1 (fr) 2006-10-06 2009-04-27 Medicament combine

Country Status (23)

Country Link
US (1) US20100008912A1 (fr)
EP (2) EP2359825A2 (fr)
JP (1) JP2010505745A (fr)
KR (1) KR20090094804A (fr)
CN (1) CN101553222A (fr)
AR (1) AR063152A1 (fr)
AU (1) AU2007307489A1 (fr)
BR (1) BRPI0717477A2 (fr)
CA (1) CA2665692A1 (fr)
CL (1) CL2007002878A1 (fr)
CO (1) CO6180429A2 (fr)
CR (1) CR10759A (fr)
EA (1) EA200970353A1 (fr)
EC (1) ECSP099311A (fr)
GE (1) GEP20115218B (fr)
IL (1) IL197883A0 (fr)
MA (1) MA30815B1 (fr)
MX (1) MX2009003660A (fr)
NO (1) NO20091628L (fr)
PE (1) PE20080977A1 (fr)
TN (1) TN2009000119A1 (fr)
TW (1) TW200823218A (fr)
WO (1) WO2008044782A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569016C (fr) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Compose heterocyclique fusionne
BRPI0813402A2 (pt) 2007-06-19 2014-12-30 Takeda Pharmaceutical Agente para evitar ou tratar um câncer resistente a trastuzumab, droga combinada, métodos para prevenir ou tratar câncer resistente a trastuzumab, para examinar a sensibilidade de um câncer expressando her2 a um inibidor de her2, para tratar um câncer em um animal julgado ter baixa sensibilidade a um inibidor de her2 e para triar uma droga para a profilaxia ou tratamento de um câncer resistente a trastuzumab, e, uso de um ou mais medicamentos.
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (fr) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Agent thérapeutique pour une tumeur cérébrale
KR101592258B1 (ko) * 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
US20180045598A1 (en) * 2016-08-09 2018-02-15 Baker Hughes Incorporated Subsea transition system
WO2021188685A1 (fr) * 2020-03-17 2021-09-23 Microvention, Inc. Agents d'embolisation liquides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP2006500391A (ja) * 2002-09-04 2006-01-05 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
CA2569016C (fr) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Compose heterocyclique fusionne
WO2005120512A2 (fr) 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Methode de traitement de cancers
CA2578384A1 (fr) * 2004-09-06 2006-03-16 Altana Pharma Ag Nouvelles pyrazolopyrimidines
JP2006275841A (ja) 2005-03-30 2006-10-12 Taiheiyo Cement Corp セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja) 2005-08-25 2007-03-08 Seiko Epson Corp 画像形成装置

Also Published As

Publication number Publication date
BRPI0717477A2 (pt) 2015-06-16
US20100008912A1 (en) 2010-01-14
JP2010505745A (ja) 2010-02-25
CN101553222A (zh) 2009-10-07
CO6180429A2 (es) 2010-07-19
WO2008044782A2 (fr) 2008-04-17
WO2008044782A3 (fr) 2008-12-11
TN2009000119A1 (en) 2010-10-18
EP2359825A2 (fr) 2011-08-24
KR20090094804A (ko) 2009-09-08
ECSP099311A (es) 2009-06-30
CA2665692A1 (fr) 2008-04-17
GEP20115218B (en) 2011-05-25
AU2007307489A1 (en) 2008-04-17
AR063152A1 (es) 2008-12-30
EP2063895A2 (fr) 2009-06-03
CR10759A (es) 2009-05-27
PE20080977A1 (es) 2008-09-05
TW200823218A (en) 2008-06-01
NO20091628L (no) 2009-06-26
MX2009003660A (es) 2009-04-22
CL2007002878A1 (es) 2008-08-01
IL197883A0 (en) 2009-12-24
EA200970353A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30815B1 (fr) Medicament combine
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
DE602005023203D1 (de) Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung
EA200501586A1 (ru) Фармацевтические продукты
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
WO2007009691A3 (fr) Combinaison de substances active s
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ECSP066649A (es) Preparado efervescente de una sustancia básica farmacéuticamente activa
MA27418A1 (fr) Ensemble de distribution de medicament.
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
SV2006002017A (es) Piperazinas derivadas de urea
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.
TW200942544A (en) Combination drug
GB0313386D0 (en) Treatment of disease
WO2006043031A3 (fr) Traitement du cancer
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
ATE459376T1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika